Mouse anti-Human HLA-A2 Monoclonal Antibody | anti-HLA-A2 antibody

Anti-HLA-A2 Alexa Fluor647

• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay
• Purity: The purified antibody is conjugated with Alexa Fluor647 under optimum conditions. The conjugate is purified by size-exclusion chromatography.
• Synonyms: HLA-A2; Monoclonal Antibody; Anti-HLA-A2 Alexa Fluor647; anti-HLA-A2 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Mouse IgG2b
• Clone Number: BB7.2
• Specificity: The antibody BB7.2 recognizes an extracellular epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.
• Purity/Purification: The purified antibody is conjugated with Alexa Fluor647 under optimum conditions. The conjugate is purified by size-exclusion chromatography.
• Form/Format: Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide

• Applicable Applications for anti-HLA-A2 antibody: Flow Cytometry (FC/FACS) (QC tested)
• Application Notes: FC/FACS: The reagent is designed for analysis of human blood cells using 5ul reagent/100ul of whole blood or 10⁶ cells in a suspension. The content of a vial (0.5 ml) is sufficient for 100 tests.
• Conjugation: Alexa Fluor647
• Immunogen: HLA-A2 solubilised by papain
• Preparation and Storage: Store in the dark at 2-8 degree C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.

Flow Cytometry (FC/FACS)

(Flow cytometry analysis (surface staining) of human peripheral blood cells using anti-HLA-A2 (BB7.2) Alexa Fluor 647.)

Related Product Information for anti-HLA-A2 antibody

HLA-A2 (44kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence.

References

*Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug;49(1):28-37., URL: https://www.ncbi.nlm.nih.gov/pubmed/8839773ordina,*Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Hum Immunol. 1998 Jul;59(7):443-50., URL: https://www.ncbi.nlm.nih.gov/pubmed/9684994ordina,*Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec;60(12):1195-206., URL: https://www.ncbi.nlm.nih.gov/pubmed/10626733ordin,*Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep;96(3):422-30., URL: https://www.ncbi.nlm.nih.gov/pubmed/10960637ordin,*Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec;3(6):453-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/17257499ordin,*Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988 Oct 15;141(8):2811-8.", URL: https://www.ncbi.nlm.nih.gov/pubmed/2459229ordina,*Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6719-23., URL: https://www.ncbi.nlm.nih.gov/pubmed/2672003ordina,*Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992 Mar;33(3):185-92., URL: https://www.ncbi.nlm.nih.gov/pubmed/1377666ordina,*Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun;23(6):1215-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/7684681ordina,*Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15;151(10):5481-91., URL: https://www.ncbi.nlm.nih.gov/pubmed/8228240ordina,*Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct;7(10):1599-605., URL: https://www.ncbi.nlm.nih.gov/pubmed/8562505ordina,*Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr;18(4):277-85., URL: https://www.ncbi.nlm.nih.gov/pubmed/2437089ordina